A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients with Advanced and/or Treatment-Refractory Solid Tumors
A study for patients with advanced and/or refractory solid tumors using oral drug CB-839
Sponsor: Calithera Biosciences, Inc
Enrolling: Male and Female Patients
IRB Number: AAAO1854
U.S. Govt. ID: NCT02071862
Contact: Kristina Lora: 646-317-5381 / ETCReferral@columbia.edu
Additional Study Information: This study is for patients with the following types of cancer: Triple negative breast cancer, non-small cell lung cancer, mesothelioma, renal cell carcinoma, melanoma, head and and neck squamous cell carcinoma, colorectal cancer, sarcoma and pancreatic cancer. The purpose of this study is to evaluate the effectiveness of the study drug CB-839 in helping patients with an advanced stage of cancer. The study will examine how the study drug is distributed, broken down and passed out of your body and will also identify the highest dose that can be given without causing severe side effects.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Do you have an advanced tumor that is relapsed and is not responsive to any available therapy? Yes No
Do you have any other current or previous malignancy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Kristina Lora